EXPRESS研究十年随访:TIA和小卒中紧急二级预防的长期影响
EXPRESS研究为前瞻性人群为基础的前后对照研究,比较紧急评估治疗(phase 2,n=281)与常规评估(phase 1,n=310)对TIA/小卒中后复发性卒中的影响。十年随访显示phase 2卒中风险仍显著降低(23.3% vs 31.6%,HR=0.68,95%CI 0.48-0.95,P=0.024),致残或致死性卒中风险亦降低(7.7% vs 13.1%,HR=0.54,95%CI 0.30-0.97,P=0.036),早期获益无衰减。
要点
- 紧急评估治疗使TIA/小卒中10年卒中风险显著降低(HR=0.68)。
- 致残或致死性卒中风险亦显著降低(HR=0.54)。
- 早期获益维持,90天后无额外获益亦无反弹。
核心结论
- TIA或小卒中紧急评估治疗可长期降低复发性卒中风险并改善结局,早期获益随时间推移无明显衰减,10年时间范围内仍具成本效益。
研究设计与样本
- EXPRESS为前瞻性人群为基础的前后对照研究,phase 1(2002年4月至2004年9月,n=310)与phase 2(2004年10月至2007年3月,n=281)比较紧急评估治疗对TIA/小卒中早期复发性卒中风险的影响,并设外部对照。
主要发现
- 10年时phase 2卒中风险仍显著降低:55/23.3% vs 82/31.6%,HR=0.68(95%CI 0.48-0.95),P=0.024。
- 致残或致死性卒中风险降低:17/7.7% vs 32/13.1%,HR=0.54(95%CI 0.30-0.97),P=0.036。
- 90天后卒中风险无额外获益亦无反弹:HR=0.88(95%CI 0.65-1.44),P=0.88;HR=0.83(95%CI 0.42-1.65),P=0.59。
- phase 2无残疾生存期望延长0.59年(95%CI 0.03-1.15),P=0.043;质量调整生存期望延长0.49年(95%CI 0.03-0.95),P=0.036。
- 10年总成本phase 2较高但无统计学意义:$1022(95%CI -3865-5907),P=0.66;每获得一个质量调整生命年额外成本$2103。
临床怎么用
- 对TIA或小卒中患者应尽快进行紧急评估与治疗,以降低长期卒中风险及致残/致死性卒中风险。
- 紧急评估治疗的早期获益可长期维持,无需担心短期获益被延迟事件抵消。
- 从10年时间范围看,该策略具有良好成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Urgent assessment aimed at reducing stroke risk after transient ischemic attack or minor stroke is cost-effective over the short-term. However, it is unclear if the short-term impact is lost on long-term follow-up, with recurrent events being delayed rather than prevented. By 10-year follow-up of the EXPRESS study (Early Use of Existing Preventive Strategies for Stroke), previously showing urgent assessment reduced 90-day stroke risk by 80%, we determined whether that early benefit was still evident long-term for stroke risk, disability, and costs. METHODS: EXPRESS was a prospective population-based before (phase 1: April 2002-September 2004; n=310) versus after (phase 2: October 2004-March 2007; n=281) study of the effect of early assessment and treatment of transient ischemic attack/minor stroke on early recurrent stroke risk, with an external control. This report assesses the effect on 10-year recurrent stroke risk, functional outcomes, quality-of-life, and costs. RESULTS: A reduction in stroke risk in phase 2 was still evident at 10 years (55/23.3% versus 82/31.6%; hazard ratio=0.68 [95% CI, 0.48-0.95]; P=0.024), as was the impact on risk of disabling or fatal stroke (17/7.7% versus 32/13.1%; hazard ratio=0.54 [0.30-0.97]; P=0.036). These effects were due to maintenance of the early reduction in stroke risk, with neither additional benefit nor rebound catch-up after 90 days (post-90 days hazard ratio=0.88 [0.65-1.44], P=0.88; and hazard ratio=0.83 [0.42-1.65], P=0.59, respectively). Disability-free life expectancy was 0.59 (0.03-1.15; P=0.043) years higher in patients in phase 2, as was quality-adjusted life expectancy (0.49 [0.03-0.95]; P=0.036). Overall, 10-year costs were nonsignificantly higher in patients attending the phase 2 clinic ($1022 [-3865-5907]; P=0.66). The additional cost per quality-adjusted life year gained in phase 2 versus phase 1 was $2103, well below current cost-effectiveness thresholds. CONCLUSIONS: Urgent assessment and treatment of patients with transient ischemic attack or minor stroke resulted in a long-term reduction in recurrent strokes and improved outcomes, with little atrophy of the early benefit over time, representing good value for money even with a 10-year time horizon. Our results suggest that other effective acute treatments in transient ischemic attack/minor stroke in the short-term will also have the potential to have long-term benefit.
引用
- Luengo-Fernandez R, Li L, Silver L, et al. Long-Term Impact of Urgent Secondary Prevention After Transient Ischemic Attack and Minor Stroke: Ten-Year Follow-Up of the EXPRESS Study. Stroke. 2021. PMID: 34706563. doi:10.1161/STROKEAHA.121.034279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。